TRIANA Biomedicines, a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, announced the successful closing of its oversubscribed $120 million Series B financing round.

TRIANA生物医学公司是一家领先的生物制药公司，专注于推进以靶点优先和邻近优先的分子胶发现平台，以解决难以成药的疾病靶点问题，该公司宣布成功完成了超额认购的1.2亿美元B轮融资。